BTIG analyst Justin Zelin maintained a Buy rating on I-MAB yesterday and set a price target of $7.00. The company’s shares closed yesterday at $5.79.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Zelin covers the Healthcare sector, focusing on stocks such as Verastem, Viking Therapeutics, and I-MAB. According to TipRanks, Zelin has an average return of 5.2% and a 36.62% success rate on recommended stocks.
I-MAB has an analyst consensus of Strong Buy, with a price target consensus of $7.40, which is a 27.81% upside from current levels. In a report released on October 6, Leerink Partners also initiated coverage with a Buy rating on the stock with a $9.00 price target.
The company has a one-year high of $6.16 and a one-year low of $0.60. Currently, I-MAB has an average volume of 2.46M.
Read More on IMAB:
Disclaimer & DisclosureReport an Issue
- I-Mab Reports H1 2025 Financial Results Amid Strategic Shift
- I-Mab initiated with an Outperform at Leerink
- I-Mab to Vote on Name Change to NovaBridge Biosciences
- Trump Trade: Offshore wind seen with no future in the U.S. under Trump
- BTIG says buy I-Mab amid ‘misperceived’ China risk
/A%20concept%20image%20of%20a%20flying%20car_%20Image%20by%20Phonlamai%20Photo%20via%20Shutterstock_.jpg)
/A%20concept%20image%20of%20space_%20Image%20by%20Canities%20via%20Shutterstock_.jpg)
/Oracle%20Corp_%20office%20logo-by%20Mesut%20Dogan%20via%20iStock.jpg)